|
Jul 11
|
Processa Pharmaceuticals, Inc. (PCSA) Secures Buy Rating on Portfolio Progress
|
|
Jul 1
|
Processa Pharmaceuticals Provides Portfolio and Business Update
|
|
Jun 17
|
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering
|
|
Jun 17
|
Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate
|
|
Apr 15
|
Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025
|
|
Oct 2
|
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
|
|
Jul 30
|
Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer
|
|
Jan 2
|
Processa Pharmaceuticals to Present at the Biotech Showcase 2024
|
|
Nov 30
|
Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference
|
|
Nov 29
|
Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook
|